Day One Biopharmaceuticals Q2 2024 Earnings Report

Day One Biopharmaceuticals EPS Results

• Actual EPS: -$0.05
• Consensus EPS: -$0.75
• Beat/Miss: Beat by +$0.70
• One Year Ago EPS: N/A

Day One Biopharmaceuticals Revenue Results

• Actual Revenue: $8.19 million
• Expected Revenue: $0.90 million
• Beat/Miss: Beat by +$7.29 million
• YoY Revenue Growth: N/A

Day One Biopharmaceuticals Announcement Details

• Quarter: Q2 2024
• Date: 7/30/2024
• Time: TAS
• Conference Call Date: Tuesday, July 30, 2024
• Conference Call Time: 7:00AM ET

Day One Biopharmaceuticals (NASDAQ:DAWN) (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development. The lead program, D1-B701, is a selective FGFR4 inhibitor designed to treat FGF19-driven hepatocellular carcinoma and other solid tumors. Additional programs include D1-H201, a selective HDAC6 inhibitor for certain hematologic malignancies, and D1-R199, a RET kinase inhibitor targeting RET fusion-positive cancers. Each program is supported by companion diagnostic strategies aimed at enriching patient populations and optimizing clinical outcomes.

Founded in 2017, Day One Biopharmaceuticals is headquartered in San Diego, California, and maintains research and development operations in both the United States and Asia. The company’s leadership team comprises professionals with extensive experience in oncology drug discovery, clinical development, regulatory affairs and commercial strategy. Day One collaborates with academic and industry partners to advance its pipeline and remains committed to addressing significant unmet needs in cancer therapeutics through scientifically rigorous and patient-focused innovation.